Treatment of cancer can affect spermatogenesis resulting in infertility. Semen cryopreservation prior to gonadotoxic treatment can be offered to secure future fertility in male cancer patients. During 20 years 1,018 patients referred for semen cryopreservation in fertile age with Hodgkin disease (n = 194), non-Hodgkin lymphoma (n = 110), leukemia (n = 126) and testicular germ cell tumor (n = 588) were followed up. Incidence of these cancers and incidence of regional semen cryopreservation was used to calculate a referral rate. Semen cryopreservation was successful in 856 of 1,018 patients (84.1%). Median yearly referral rate was respectively 17% and 31% in hematological malignancies and testicular germ cell tumor. Regional referral rate in hematological malignancies dropped dramatically after 2005 to a minimum of 2% in 2009. The incidence of TGCT and referral rate for fertility preservation in these patients increased over time. Our result show that referral of for semen cryopreservation in patients with hematological malignancies in fertile age is suboptimal.

Additional Metadata
Keywords fertility, hematological malignancies, referral, semen cryopreservation, testicular germ cell tumors
Persistent URL,
Journal Tijdschrift voor Urologie
Vinken, S.P.T. (Stefanus P. T.), Boellaard, W.P.A, Dohle, G.R, & Dinkelman-Smit, M. (2018). 20 years of semen cryopreservation: feasibility and referral behavior 20 jaar semencryopreservatie: haalbaarheid en verwijspatronen. Tijdschrift voor Urologie, 8(5), 81–87. doi:10.1007/s13629-018-0204-9